Scarica l'app Stockscreener
1.25
3.85%
-0.05
Dopo l'orario di chiusura:
1.26
0.01
+0.80%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Up 7.6% in January - MarketBeat
Cancer Gene Therapy Market Growth, and Forecast through - openPR
Editas Medicine, Inc. to Host Earnings Call - ACCESS Newswire
Top 5 CRISPR Companies To Invest In (February 2025) - Securities.io
Leerink Partnrs Comments on Editas Medicine FY2025 Earnings - MarketBeat
FY2024 EPS Estimate for Editas Medicine Decreased by Analyst - MarketBeat
Brokers Offer Predictions for Editas Medicine FY2025 Earnings - MarketBeat
Beta Thalassemia Market on Track for Major Expansion by 2034, According to DelveInsight | Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma, Acceleron Pharma, Bristol-Myers - Barchart
Beta Thalassemia Market on Track for Major Expansion by 2034, - openPR
Analysts Issue Forecasts for Editas Medicine FY2025 Earnings - MarketBeat
Hennion & Walsh Asset Management Inc. Has $340,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential (NASDAQ:EDIT) - Seeking Alpha
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Position Lifted by Barclays PLC - Defense World
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers - Seeking Alpha
International Assets Investment Management LLC Trims Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas, after slow start, outlines plan to catch other CRISPR companies - STAT
Editas Medicine stock hits 52-week low at $1.16 amid steep decline - Investing.com Australia
Editas Medicine Outlines 2025 Strategic Priorities and Milestones - Yahoo Finance
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Yahoo Finance
Editas Medicine stock hits 52-week low at $1.16 amid steep decline By Investing.com - Investing.com South Africa
CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10+ Major Market Players - Yahoo Finance UK
Editas Medicine advances gene editing treatments - Investing.com
Editas Medicine (EDIT) Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - StreetInsider.com
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - The Manila Times
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key - The Bakersfield Californian
Editas Medicine Highlights New In Vivo Preclinical Proof of - GlobeNewswire
Editas Medicine Achieves Major Gene Editing Breakthrough in Primate Study, Sets 2027 Roadmap - StockTitan
Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline - Fierce Biotech
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Editas Medicine To Present At The 43rd Annual J.P. Morgan Healthcare Conference - Barchart
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Editas Medicine CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Lowers Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Up 5.4% in December - Defense World
Short Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 5.4% - MarketBeat
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
State Street Corp Cuts Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by State Street Corp - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $7.00 Average PT from Brokerages - MarketBeat
Editas Medicine (STU:8EM) Cyclically Adjusted FCF per Share : €-1.69 (As of Sep. 2024) - GuruFocus.com
Editas Medicine stock plunges to 52-week low of $1.27 - Investing.com
Cambridge company is laying of 180 people, 65% of its workforce - MSN
Editas Medicine's SWOT analysis: gene editing firm pivots strategy amid stock uncertainty - Investing.com
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program - MSN
1.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):